Anti-nucleosome antibodies have a role in the diagnosis and follow-up of @entity1252 ( @entity1252 ) and have a possible correlation with @entity1252 activity and with kidney and hematological involvement. The aim of our study was to detect in 91 @entity1 with @entity309 ( @entity309 ) the positivity of anti-nucleosome antibodies during therapy with three different @entity310 blocking agents and to underline the possible correlation with the development of antinuclear autoantibodies (ANA) and anti-dsDNA autoantibodies. We detected anti-nucleosome antibodies, ANA, and anti-dsDNA during therapy with three different @entity310 blocking agents at T-0 and after 12 and 24 weeks of treatment, respectively. Anti-nucleosome antibodies (IgG class) were analyzed by ELISA technique (Orgentec Diagnostika GmbH, Mainz, Germany), ANA both by indirect immunofluorescence (IIF) technique on Hep-2 (Scimedx, USA) and by ELISA (Autoimmune EIA ANA screening test Bio-Rad Laboratories, CA, USA), and anti-dsDNA (IgG and IgM classes) by ELISA (Kallestad, Bio-Rad Laboratories, CA, USA) and confirmed by IIF on Crithidia luciliae (ImmunoConcepts N.A., Sacramento, CA, USA). We observed 19 @entity1 on infliximab treatment at 3 mg/kg every 8 weeks, 43 @entity1 on etanercept treatment at 25 mg twice a week, and 29 @entity1 on adalimumab treatment at 40 mg every other week. At baseline, we observed positivity as follow: in the group of @entity1 treated with infliximab-anti-nucleosome 1/19 (5.26%), ANA 3/19 (15.7%), anti-dsDNA 1/19 (5.26%); in the group treated with etanercept--anti-nucleosome 2/43 (4.65%), ANA 1/43 (2.43%), anti-dsDNA 0/43; and in the group treated with adalimumab--anti-nucleosome 2/29 (6.89%), ANA 1/29 (3.44%), anti-dsDNA 0/29. The results at 12 weeks for the three autoantibodies were: for infliximab--3/19 (15.7%), 10/19 (52.6%), 2/19 (10.5%); for etanercept--3/43 (6.9%), 10/43 (23.2%), 1/43 (2.32%); and for adalimumab--3/29 (10.3%), 4/29 (13.7%), 1/29 (3.4%). At 24 weeks, the results were for infliximab 6/19 (31.5%), 12/19 (63.1%), 2/19 (10.5%); for etanercept 11/43 (25.5%), 22/43 (51.1%), 2/43 (4.65%); and for adalimumab 4/29 (13.7%), 13/29 (44.8%), 1/29 (3.4%). We observed a concordance anti-nucleosome/ANA antibodies of 85.5% (p < 0.001). Our data showed a concordance between anti-nucleosome antibodies and ANA positivity in @entity1 with @entity309 during therapy with @entity310 blocking agents. The induction of autoantibodies positivity is different for each @entity310 blocking agent.

Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different XXXX blocking agents in @entity309 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity310 :: ('7124', 'Gene') :: ['TNFalpha'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity310 :: (7124,Gene) :: ['TNFalpha']
